Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) has shared an announcement.
Evaxion Biotech has announced the sale of 696,400 American Depositary Shares at an average price of USD $7.1776 per ADS in an at-the-market offering, raising approximately $4.85 million after fees and expenses. This transaction, completed on January 24, 2025, led to an increase in the company’s share capital, prompting an amendment to its Articles of Association effective January 27, 2025, to reflect the capital increase.
More about Evaxion Biotech
Evaxion Biotech A/S is a Danish company focused on developing advanced software to create novel immune therapies and vaccines.
YTD Price Performance: 42.69%
Average Trading Volume: 1,090,527
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.07M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.
